Experimental KRAS drug trial halted early: what we know
NCT ID NCT06599502
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-stage study tested a new drug called AZD0022, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (KRASG12D). The main goal was to check safety and find the right dose. The study was stopped early after enrolling only 17 participants, so we have limited information on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
New York, New York, 10016, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Seoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.